Schauer P K, Straus D J, Bagley C M, Rudolph R H, McCracken J D, Huff J, Glucksburg H, Bauermeister D E, Clarkson B D
Cancer. 1981 Dec 1;48(11):2493-8. doi: 10.1002/1097-0142(19811201)48:11<2493::aid-cncr2820481124>3.0.co;2-t.
The clinical features of 13 patients with angioimmunoblastic lymphadenopathy were analyzed to determine prognostic factors and response to therapy. Eleven patients presented with sudden onset of fever, weight loss, generalized lymphadenopathy, and hepatosplenomegaly. Laboratory features included autoimmune hemolytic anemia and polyclonal hypergammaglobulinemia. Pulmonary involvement was seen in six cases and skin rash in four. Two patients had localized lymphadenopathy without systemic symptoms. Both are alive at 5.5 and 2.5 years, respectively, after diagnosis, although the latter patient has required intermittent prednisone for recurrent lymphadenopathy. An additional patient is alive on treatment for months following diagnosis. The remaining ten have died, nine of sepsis and one of cerebral hemorrhage. The immunosuppression and myelosuppression of combination chemotherapy may have hastened their deaths. An individualized, conservative treatment approach is recommended.
分析13例血管免疫母细胞性淋巴结病患者的临床特征,以确定预后因素及对治疗的反应。11例患者表现为突然发热、体重减轻、全身淋巴结肿大及肝脾肿大。实验室检查特征包括自身免疫性溶血性贫血和多克隆高球蛋白血症。6例有肺部受累,4例有皮疹。2例患者有局限性淋巴结肿大,无全身症状。诊断后,这2例患者分别存活了5.5年和2.5年,不过后1例患者因复发性淋巴结肿大需要间歇性使用泼尼松。另有1例患者诊断后接受治疗数月仍存活。其余10例患者已死亡,9例死于败血症,1例死于脑出血。联合化疗的免疫抑制和骨髓抑制作用可能加速了他们的死亡。建议采用个体化的保守治疗方法。